Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The EPOCH Study: Phase II Open Labelled Study Investigating the Use of Single Agent Eribulin and Eribulin in Combination With Pembrolizumab in Relapsed Tubo-ovarian or Uterine Carcinosarcoma

NCT05619913 is registered in ClinicalTrials.gov with Australia New Zealand Gynaecological Oncology Group as lead sponsor.

NCT NCT05619913
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05619913 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The EPOCH Study: Phase II Open Labelled Study Investigating the Use of Single Agent Eribulin and Eribulin in Combination With Pembrolizumab in Relapsed Tubo-ovarian or Uterine Carcinosarcoma
Lead sponsor
Australia New Zealand Gynaecological Oncology Group
Phase
Phase 2
Overall status
Completed
Start date
May 22, 2023
Completion date
May 15, 2026
Enrollment
13 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian carcinosarcoma, uterine carcinosarcoma